EA200601641A1 - CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE - Google Patents

CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE

Info

Publication number
EA200601641A1
EA200601641A1 EA200601641A EA200601641A EA200601641A1 EA 200601641 A1 EA200601641 A1 EA 200601641A1 EA 200601641 A EA200601641 A EA 200601641A EA 200601641 A EA200601641 A EA 200601641A EA 200601641 A1 EA200601641 A1 EA 200601641A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxalate
particles
escytal
premax
composition containing
Prior art date
Application number
EA200601641A
Other languages
Russian (ru)
Inventor
Ким Бейструп Енсен
Рикке Эва Хумбле
Кен Лильегрен
Троэльс Вольсгорд Кристенсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34921251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200601641A1 publication Critical patent/EA200601641A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении описаны кристаллические частицы оксалата эсциталопрама, имеющие широкое распределение размера частиц или содержащие 0,01% (мас./мас.) Z-4-(4-диметиламино-1-(4-фторфенил)бут-1-енил)-3-гидроксиметилбензонитрила, где указанные частицы пригодны для применения в непосредственном прессовании. Кроме того, в изобретении описана новая фармацевтическая единичная дозированная форма, содержащая такие кристаллические частицы оксалата эсциталопрама, а также способы получения таких кристаллических частиц оксалата эсциталопрама. Наконец, изобретение относится к способу уменьшения количества гидроксилсодержащих примесей в растворе циталопрама и эсциталопрама.The present invention describes crystalline escitalopram oxalate particles having a wide particle size distribution or containing 0.01% (w / w) Z-4- (4-dimethylamino-1- (4-fluorophenyl) but-1-enyl) - 3-hydroxymethylbenzonitrile, where these particles are suitable for use in direct compression. In addition, the invention describes a new pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate, as well as methods for producing such crystalline particles of escitalopram oxalate. Finally, the invention relates to a method for reducing the amount of hydroxyl-containing impurities in a solution of citalopram and escitalopram.

EA200601641A 2004-03-05 2005-02-21 CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE EA200601641A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55090904P 2004-03-05 2004-03-05
DKPA200400382 2004-03-05
PCT/DK2005/000115 WO2005084643A1 (en) 2004-03-05 2005-02-21 Crystalline composition containing escitalopram oxalate

Publications (1)

Publication Number Publication Date
EA200601641A1 true EA200601641A1 (en) 2006-12-29

Family

ID=34921251

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601641A EA200601641A1 (en) 2004-03-05 2005-02-21 CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE

Country Status (9)

Country Link
EP (1) EP1732514A1 (en)
JP (1) JP2007526262A (en)
AU (1) AU2005218713B2 (en)
BR (1) BRPI0508266A (en)
CA (1) CA2558198A1 (en)
EA (1) EA200601641A1 (en)
NO (1) NO20064499L (en)
NZ (1) NZ549100A (en)
WO (1) WO2005084643A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
CA2672925A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
EP2116231A1 (en) * 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
JP2018016569A (en) * 2016-07-26 2018-02-01 株式会社トクヤマ Production method of (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
JP6554245B1 (en) * 2019-01-31 2019-07-31 第一工業製薬株式会社 2,2'-bis (2-hydroxyethoxy) -1,1'-binaphthalene powder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
MXPA03008777A (en) * 2001-05-01 2004-02-12 Lundbeck & Co As H The use of enantiomeric pure escitalopram.
AR034612A1 (en) * 2001-06-25 2004-03-03 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM
KR20040028947A (en) * 2001-07-31 2004-04-03 하. 룬트벡 아크티에 셀스카브 Crystalline composition containing escitalopram
PE20040991A1 (en) * 2002-08-12 2004-12-27 Lundbeck & Co As H SEPARATION OF INTERMEDIARIES FOR THE PREPARATION OF ESCITALOPRAM
WO2004056791A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate

Also Published As

Publication number Publication date
AU2005218713B2 (en) 2009-11-19
NO20064499L (en) 2006-12-04
NZ549100A (en) 2010-02-26
CA2558198A1 (en) 2005-09-15
BRPI0508266A (en) 2007-07-31
JP2007526262A (en) 2007-09-13
WO2005084643A1 (en) 2005-09-15
AU2005218713A1 (en) 2005-09-15
EP1732514A1 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
BR0206164A (en) Escitalopram oxalate crystalline particles, method for the production of escitalopram oxalate crystalline particles, and solid unit dosage form
TW200612892A (en) Novel compounds
TW200407305A (en) Novel compounds
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
MX2007013065A (en) Dihydrobenzofuran derivatives and uses thereof.
MXPA04003858A (en) Mch antagonists for the treatment of obesity.
MY142029A (en) Phenoxyacetic acid derivatives
EA200701123A1 (en) METHOD OF CLEANING TRANS - (-) - Δ-TETRAHYDROCANNABINOL AND TRANS - (+) - Δ-TETRAHYDROCANNOBINOL
MA33044B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, ITS GALENIC DOSAGE FORM, PREPARATION METHOD AND USES FOR ENHANCED GLYCEMIC REGULATION IN PATIENT
RU2011117019A (en) COMPOSITIONS FOR CARE OF THE ORAL CAVITY CONTAINING SPHERICAL PARTICLES OF AMORPHIC QUARTZ
SE0203713D0 (en) Novel compounds
MXPA05007182A (en) Complexes of protein crystals and ionic polymers.
WO2004108133A3 (en) Modulators of vr1 receptor
MXPA04004464A (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease.
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
MX2007005710A (en) Hydroxybenzoate salts of metanicotine compounds.
TW200502221A (en) Novel lactams and uses thereof
EA200601641A1 (en) CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE
SG155046A1 (en) Process for modifying drug crystal formation
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EP1423414A4 (en) Novel depsipeptides and process for preparing same
HK1121670A1 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
NO20053673L (en) New anticonvulsant derivatives salts